#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

2018-10-17 · 64 min · episode 22 · 13 entities

episode page audio

Asserted relationships

→ hosted by Peter Attia, MD person

0.55

evidence rules-v4
Feed author/publisher: Peter Attia, MD
→ discusses Health & Fitness concept

0.40

evidence rules-v4
Feed category: Health & Fitness
→ discusses Medicine concept

0.40

evidence rules-v4
Feed category: Medicine
→ discusses Fitness concept

0.40

evidence rules-v4
Feed category: Fitness

Entities found in this episode

concepts 11

mentioned Health & Fitness concept

0.50

evidence rules-v4
Feed category: Health & Fitness
mentioned Medicine concept

0.50

evidence rules-v4
Feed category: Medicine
mentioned Fitness concept

0.50

evidence rules-v4
Feed category: Fitness
discusses Health & Fitness concept

0.40

evidence rules-v4
Feed category: Health & Fitness
discusses Medicine concept

0.40

evidence rules-v4
Feed category: Medicine
discusses Fitness concept

0.40

evidence rules-v4
Feed category: Fitness
mentioned III concept

0.35

evidence rules-v4
III
mentioned HDL concept

0.35

evidence rules-v4
HDL
mentioned CETP concept

0.35

evidence rules-v4
CETP
mentioned FACP concept

0.35

evidence rules-v4
FACP
mentioned FNLA concept

0.35

evidence rules-v4
FNLA

persons 2

mentioned Peter Attia, MD person

0.70

evidence rules-v4
Feed author/publisher: Peter Attia, MD
hosted by Peter Attia, MD person

0.55

evidence rules-v4
Feed author/publisher: Peter Attia, MD

Episode description as stored

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials. We discuss: Reverse cholesterol transport [1:40]; Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00]; Remnant lipoproteins and apoC-III [16:45]; Particles having sex: lipid exchange [28:00]; Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45]; 2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45]; 2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15]; 2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and More. Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram .